ResMed stock climbs after earnings beat as analysts see valuation full
Published on 08/20/2026 at 13:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. (US7611521078) stock stayed elevated after a post-earnings rally, trading around $230 per share as of August 19, 2026, following a better-than-expected quarterly profit that pushed the shares up 4.8% in one session.
Earnings beat but revenue just misses
In its fiscal fourth-quarter results reported in mid-August 2026, ResMed delivered non-GAAP earnings of $2.95 per share, beating a consensus forecast of $2.89 per share and signaling continued margin discipline in its sleep and respiratory care portfolio, according to a coverage summary on a financial news platform.
The same update noted that revenue for the fiscal fourth quarter reached $1.46 billion, slightly below the anticipated $1.47 billion, indicating that top-line growth fell short of analyst expectations even as profitability outperformed.
This combination of an earnings beat and a narrow revenue miss frames a nuanced picture for investors: cost control and product mix supported stronger earnings per share than expected, while demand trends were solid but not enough to surpass the revenue consensus by the end of the quarter.
Analyst coverage and valuation context
A recent analyst note summarized on an investing portal highlighted new coverage of ResMed stock with a Neutral rating and a price target of $230.00 per share, effectively matching where the shares were trading in mid-August 2026.
That assessment emphasized that the firm sees limited meaningful upside versus existing consensus estimates at current levels, characterizing the valuation as full even though some valuation models that combine multiple approaches suggest the company may be undervalued based on fair value calculations.
With the stock closing at $230.84 on August 19, 2026, the same forecast overview indicated that the average published price target implies only 3.70 percent upside from that close, underscoring that many analysts expect modest gains rather than a dramatic re-rating from here.
Short-term price action after results
Market data from another performance review showed that on August 19, 2026, ResMed shares rose 4.8 percent intraday to a quoted level of $230.65, reflecting investor enthusiasm following the earnings beat and the confirmation that margins remain resilient.
A separate sector-consensus snapshot for ResMed on a major derivatives venue listed a last price of $230.66 in U.S. dollars at 3:59:54 p.m. Eastern time on August 19, 2026, with a five-day percentage change of plus 4.84 percent, indicating that most of the recent move has occurred in the days around the latest results.
The same sector overview also showed that the stock’s performance from January 1, 2026, stood at a negative 2.13 percent as of August 19, 2026, meaning the recent rally has reduced but not erased the year-to-date decline, leaving ResMed trading slightly below where it started the year.
Technical signals supporting the move
A market commentary published on August 20, 2026, reviewing ResMed’s recent action reported that the stock moved up by 3.43 percent on August 19, 2026, and pointed to momentum indicators such as MACD and Williams %R generating buy signals in the short term.
Those technical readings are consistent with the sharp one-day advance of 4.8 percent highlighted in another valuation-focused article, suggesting that the combination of an earnings beat and improving chart signals has drawn in traders looking to capitalize on near-term strength.
For longer-term holders, however, the modest 3.70 percent implied upside to the average price target and the characterization of the stock as fully valued at a price-to-earnings ratio of 21.2 and a price/earnings-to-growth ratio of 2.15 suggest that expectations are now more measured, with future gains likely tied to execution rather than multiple expansion alone.
Sleep apnea solutions remain core
ResMed Inc.’s core business revolves around devices and software for the diagnosis and treatment of sleep-disordered breathing, particularly obstructive sleep apnea, alongside related respiratory care solutions and connected health platforms.
Its flagship products in this area include positive airway pressure devices and accompanying masks designed to keep airways open during sleep, supported by cloud-connected monitoring tools that help clinicians track adherence and adjust therapy for millions of patients worldwide.
This focus on chronic conditions that require ongoing management helps underpin ResMed’s recurring revenue streams and contributes to the earnings resilience seen in the latest fiscal fourth-quarter figures, even when revenue growth falls slightly short of consensus expectations.
ResMed stock level and investor take
Based on the CBOE sector-consensus listing, ResMed stock last traded at $230.66 at 3:59:54 p.m. Eastern time on August 19, 2026, in U.S. dollars, close to the $230.84 closing price reported by another market-data overview for the same date.
Investors weighing the shares at this level see a company that has just delivered a non-GAAP earnings beat of $0.06 per share versus expectations in its latest fiscal fourth quarter, coupled with a revenue miss of $0.01 billion, and a year-to-date share price still down 2.13 percent despite a five-day gain of 4.84 percent and a one-day move of up to 4.8 percent.
Company fact box
Company: ResMed Inc.
ISIN: US7611521078
Ticker: RMD
Exchange: NYSE
Price (as of August 19, 2026, 3:59 p.m. ET): $230.84 USD
Market cap: [value not specified in available sources]
Sector / Industry: Health care equipment and services, medical devices
Index membership: [specific index membership not specified in available sources]
